Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Drug susceptibility profiles of recombinant vaccinia virus harboring mutation(s) conferring resistance to cidofovir — Graciela Andreï (2006) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Drug susceptibility profiles of recombinant vaccinia virus harboring mutation(s) conferring resistance to cidofovir
Shared by
De Clercq Erik
KU Leuven
Drug susceptibility profiles of recombinant vaccinia virus harboring mutation(s) conferring resistance to cidofovir
Article
2006
en
Authors
+4 more
GA
Graciela Andreï
DG
Don B. Gammon
PF
Pierre Fiten
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2006
Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulencein Mice
Graciela Andreï
,
Don B. Gammon
,
Pierre Fiten
,
De Clercq Erik
,
Ghislain Opdenakker
,
Robert Snoeck
,
David H. Evans
Article
2008
Mechanism of Antiviral Drug Resistance of Vaccinia Virus: Identification of Residues in the Viral DNA Polymerase Conferring Differential Resistance to Antipoxvirus Drugs
Don B. Gammon
,
Robert Snoeck
,
Pierre Fiten
,
Marcela Krečmerová
,
Antonı́n Holý
,
De Clercq Erik
,
Ghislain Opdenakker
,
David H. Evans
,
Graciela Andreï
Article
2005
Reduced pathogenicity of phenotypically and genotypically characterized cidofovir (CDV)-resistant vaccinia virus (VV)
Graciela Andreï
,
Pierre Fiten
,
De Clercq Erik
,
Ghislain Opdenakker
,
Robert Snoeck
Article
1991
Highly Efficient Expression of Proteins Encoded by Recombinant Vaccinia Virus in Lymphocytes
J.M. Alonso
,
Javier M. Rodrı́guez
,
Eladio Viñuela
,
Guido Guido Kroemer
,
Carlos Martı́nez-A
Article
2004
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360
Valery Fikkert
,
Anneleen Hombrouck
,
Barbara Van Remoortel
,
Marc De Maeyer
,
Christophe Pannecouque
,
De Clercq Erik
,
Zeger Debyser
,
Myriam Witvrouw
Discussion(0)
No comments yet. Be the first to comment.